I’m passing along a tip about an article on China entry strategies for U.S. pharma start-ups. I thought you might be interested because of its focus on pharma, a novelty for our blog which focuses more on public health and hospital investment.
The article is called “Life Sciences Companies Go to China to Raise Capital” and it can be found on Asia Healthcare Blog, which should come up first on your google search if you query “Asia healthcare”.
Feel free to e-mail me if you have any questions about the article or our website.
john cochrane
Any comments about the change in the Phase II trial for Arn-509. Now a 3-arm trial with comparisons different from any I have seen in PCa at any phase. Is this a market positioning trial? A new paradigm that recognizes pre-chemo as the insertion location? Have the arms have too few members?
